Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.77 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.77 |
| ▸ | PI4KA | P42356 | 2/20 | 0.77 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.77 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.77 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.77 |
| ▸ | DPP4 | P27487 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.77 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.77 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.77 |
| ▸ | GAPDH | P04406 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.77 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.77 |
| ▸ | STAT6 | P42226 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.77 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546471 | 1.00 | ADORA3 (0.77) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL5053230 | 0.91 | ADORA3 (0.77) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL23414488 | 0.91 | ADORA3 (0.77) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL4658306 | 0.91 | ADORA3 (0.77) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL26130573 | 0.91 | ADORA3 (0.77) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL23050294 | 0.90 | ADORA3 (0.75) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL24538798 | 0.90 | ADORA3 (0.75) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL25936 | 0.90 | ADORA3 (0.75) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL12031327 | 0.90 | ADORA3 (0.75) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL23880679 | 0.90 | ADORA3 (0.75) | ADORA3ADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1493818-A2 | Nucleoside triphosphates and their incorporation into ribozymes | RIBOZYME PHARMACEUTICALS, INC. (US) | 2005-01-05 | — | — | EP | claimed |
| JP-2004512810-A | — | — | 2004-04-30 | — | — | JP | claimed |
| US-6509460-B1 | Contacting the modified nucleotide triphosphate with a mixture comprising a nucleic acid template, an RNA polymerase enzyme, and an enhancer of modified nucleotide triphosphate incorporation | RIBOZYME PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | claimed |
| EP-1212416-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| JP-2002512794-A | — | — | 2002-05-08 | — | — | JP | claimed |
| WO-2001016312-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| EP-1073732-A2 | NUCLEOSIDE TRIPHOSPHATES AND THEIR INCORPORATION INTO RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-02-07 | — | — | EP | claimed |
| US-6127535-A | FOR THE INCORPORATION OF MODIFIED (NON-STANDARD) AND UNMODIFIED NUCLEOTIDES INTO NUCLEIC ACIDS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | claimed |
| WO-1999055857-A2 | NUCLEOSIDE TRIPHOSPHATES AND THEIR INCORPORATION INTO RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-11-04 | — | — | WO | claimed |
| EP-1493818-A2 | Nucleoside triphosphates and their incorporation into ribozymes | RIBOZYME PHARMACEUTICALS, INC. (US) | 2005-01-05 | — | — | EP | disclosed |
| US-6617438-B1 | Nucleic acid of given formula; ribozyme able to cleave RNA of HER2 gene; use as anticarcinogenic agent | SIRNA THERAPEUTICS, INC. | 2003-09-09 | — | — | US | disclosed |
| EP-1321521-A1 | Ribozymes directed against flt-1 | RIBOZYME PHARMACEUTICALS, INC. (US) | 2003-06-25 | — | — | EP | disclosed |
| US-6528640-B1 | Of given formula; can use to inhibit HER2/neu/ ErbB2 gene expression; anticarcinogenic agents | RIBOZYME PHARMACEUTICALS, INCORPORATED | 2003-03-04 | — | — | US | disclosed |
| US-6509460-B1 | Contacting the modified nucleotide triphosphate with a mixture comprising a nucleic acid template, an RNA polymerase enzyme, and an enhancer of modified nucleotide triphosphate incorporation | RIBOZYME PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | disclosed |
| US-20030004122-A1 | Nucleotide triphosphates and their incorporation into oligonucleotides | RIBOZYME PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| US-6482932-B1 | Nucleoside triphosphates and their incorporation into oligonucleotides | RIBOZYME PHARMACEUTICALS, INCORPORATED | 2002-11-19 | — | — | US | disclosed |
| US-6127535-A | FOR THE INCORPORATION OF MODIFIED (NON-STANDARD) AND UNMODIFIED NUCLEOTIDES INTO NUCLEIC ACIDS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0980424-A2 | ENZYMATIC NUCLEIC ACIDS: SYNTHESIS, SELECTION AND USE | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998050530-A2 | ENZYMATIC NUCLEIC ACIDS: SYNTHESIS, SELECTION AND USE | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004122-A1 | Nucleotide triphosphates and their incorporation into oligonucleotides | NTPCR, DNTT, RNGTT | ADORA3 161/4885ADORA1 184/4885PI4KA 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.